The effects of IDRA 21, a positive modulator of the AMPA receptor, on delayed matching performance by young and aged rhesus monkeys

  title={The effects of IDRA 21, a positive modulator of the AMPA receptor, on delayed matching performance by young and aged rhesus monkeys},
  author={Jerry J. Buccafusco and Thomas Weiser and Karin Winter and Klaus Klinder and Alvin V. Terry},

AMPA Receptor Modulation for Enhancing Plasticity and Treating Neuropathology

Evidence that the compounds are effective in animal models of psychiatric disorders associated with abnormal brainstem activity is in agreement with this hypothesis, and positive modulators increase the production of brain growth factors that promote plasticity and neuronal viability.

Therapeutic potential of positive AMPA modulators and their relationship to AMPA receptor subunits. A review of preclinical data

  • M. Black
  • Biology, Psychology
  • 2004
Preclinical work on positive AMPA modulators is reviewed to suggest that positive modulation of AMPA may offer numerous therapeutic avenues for central nervous system drug discovery.

Evaluation of the pro-cognitive effects of the AMPA receptor positive modulator, 5-(1-piperidinylcarbonyl)-2,1,3-benzoxadiazole (CX691), in the rat

Data support the pro-cognitive activity reported for AMPA receptor positive modulators and suggest that these compounds may be of benefit in treating disorders characterised by cognitive deficits such as Alzheimer’s disease and schizophrenia.

The AMPA modulator S 18986 improves declarative and working memory performances in aged mice

The memory-enhancing properties of S 18986 are confirmed and, in line with emerging data on multiple AMPA modulators, the relevance of targeting AMPA receptors in the development of new memory enhancers is highlighted.

DRUG FOCUS: S 18986: A Positive Allosteric Modulator of AMPA‐Type Glutamate Receptors Pharmacological Profile of a Novel Cognitive Enhancer

S 18986, a new selective positive allosteric modulator of AMPA‐type glutamate receptors, increased induction and maintenance of LTP in the hippocampus as well as the expression of brain‐derived neurotrophic factor (BDNF) both in vitro and in vivo.

The effects of huperzine A and IDRA 21 on visual recognition memory in young macaques

The dopamine D3 receptor antagonist, S33138, counters cognitive impairment in a range of rodent and primate procedures.

Although dopamine D(3) receptor antagonists have been shown to enhance frontocortical cholinergic transmission and improve cognitive performance in rodents, data are limited and their effects have

Piracetam, an AMPAkine drug, facilitates memory consolidation in the day-old chick



Effect of the AMPA receptor modulator IDRA 21 on LTP in hippocampal slices

The hypothesis that drugs which enhance AMPA receptor-mediated currents facilitate LTP is supported, as at concentrations that facilitated synaptic transmission, IDRA 21 promoted the induction of LTP.

Facilitative Effects of the Ampakine CX516 on Short-Term Memory in Rats: Enhancement of Delayed-Nonmatch-to-Sample Performance

Evidence that ampakines cause a cumulative enhancement of performance in a spatial short-term memory task is described and evaluation of errors suggests that the ampakine eliminated the necessity for a shift in response strategy that produced proactive interference on the following trial.

Facilitative Effects of the Ampakine CX516 on Short-Term Memory in Rats: Correlations with Hippocampal Neuronal Activity

Firing correlates of simultaneously recorded cells in the CA1 and CA3 fields of the hippocampus over the period in which DNMS performance was facilitated by CX516 are reported, which shows firing increases were restricted to correct trials only and were largest on trials with long delays.

BIIR 561 CL: a novel combined antagonist of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors and voltage-dependent sodium channels with anticonvulsive and neuroprotective properties.

Data show that BIIR 561 CL is a combined antagonist of AMPA receptors and voltage-gated sodium channels with promising anticonvulsive and neuroprotective properties.

Multiple central nervous system targets for eliciting beneficial effects on memory and cognition.

Certain memory-enhancing agents may prove more useful when implemented early in the course of a disease such as AD, and they also may enjoy a wide application for the treatment of the memory decline associated with normal aging.

Modulating Excitatory Synaptic Neurotransmission: Potential Treatment for Neurological Disease?

This review attempts to synthesize a variety of studies that have utilized these AMPA modulators to gain insight into fundamental as well as clinically relevant AMPA receptor-mediated processes.

Improvement in performance of a delayed matching-to-sample task by monkeys following ABT-418: a novel cholinergic channel activator for memory enhancement

ABT-418 represents a prototype of a new class of nicotinic agonists designed for the potential treatment of human dementias having a low profile of toxicity.

Pharmacologic rationale for memantine in chronic cerebral hypoperfusion, especially vascular dementia.

  • H. Möbius
  • Biology, Medicine
    Alzheimer disease and associated disorders
  • 1999
Preclinical data presented in this paper indicate that benefits in both Alzheimer disease and vascular dementia can be achieved with Memantine, and phase II clinical data in dementia are summarized, and two ongoing pivotal trials in VaD are described.

The preclinical pharmacological profile of WAY-132983, a potent M1 preferring agonist.

Oral WAY-132983 exhibited cognitive benefit at doses lower than those producing undesirable effects; therefore, it is a potential candidate for improving the cognitive status of patients with Alzheimer's disease.